1. Safety and efficacy of oral antiplatelet for patients who had acute ischaemic stroke undergoing endovascular therapy
- Author
-
Yongjun Wang, Jing Jing, Xiaochuan Huo, Anxin Wang, Yilong Wang, Raynald, Miao Zhongrong, Feng Gao, Ma Ning, and Dapeng Mo
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Intracranial haemorrhage ,030204 cardiovascular system & hematology ,Lower risk ,Endovascular therapy ,lcsh:RC346-429 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Ischaemic stroke ,medicine ,Stroke ,lcsh:Neurology. Diseases of the nervous system ,Original Research ,business.industry ,Tirofiban ,Thrombolysis ,medicine.disease ,stroke ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background and purposeTo investigate the safety and efficacy of oral antiplatelet therapy (APT) for patients who had acute ischaemic stroke (AIS), receiving endovascular therapy (EVT).MethodsPatients were divided into non-APT group and APT (single APT or dual APT (DAPT)) group. The safety and efficacy endpoints at 3-month follow-up were symptomatic intracranial haemorrhage (sICH), recanalisation rate, clinical outcome and mortality.ResultsAmong 915 patients who had AIS, those in APT group (n=199) showed shorter puncture-to-recanalisation time, lower frequency of intravenous thrombolysis and more use of tirofiban compared with those in non-antiplatelet group (n=716) (pConclusionsOral APT prior to undergoing EVT is safe and may accompany with superior clinical outcomes. DAPT may associate with superior clinical outcomes and lower risk of mortality.
- Published
- 2020